Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE® mobile health study

Bernardo Sousa-Pinto; Aiste Ramanauskaite; Sophia Neisinger; Ellen Witte-Haendel; Ana M. Gimenez-Arnau; Carole Guillet; Claudio Alberto S. Parisi; Constance H. Katelaris; Daria Fomina; Desiree Larenas-Linnemann; Elizabeth Garcia; Emek Kocaturk; Frank Siebenhaar; Hermenio Lima; Igor Kaidashev; Iman Nasr; Isabel Ogueta Canales; Ivan Cherrez Ojeda; Jacques Hebert; Jean Bousquet; Jonathan A. Bernstein; Jonny Peter; Jorge Sanchez; Jose Ignacio Larco Sousa; Kanokvalai Kulthanan; Karsten Weller; Kiran Godse; Krzysztof Rutkowski; Lasma Lapina; Laurence Bouillet; Leo Lianyi Han; Luis Felipe Ensina; Margarida Goncalo; Markus Magerl; Martijn van Doorn; Martin Metz; Maryam Khoshkhui; Michihiro Hide; Murat Turk; Niall Conlon; Pascale Salameh; Pavel Kolkhir; Riccardo Asero; Roman Stepanenko; Sabine Altrichter; Sara Gil-Mata; Simon Francis Thomsen; Torsten Zuberbier; Vladyslav Tsaryk; Young-Min Ye; Zenon Brzoza; Zuotao Zhao; Marcus Maurer

doi:10.1111/all.16371

Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE® mobile health study

Bernardo Sousa-Pinto^*, Aiste Ramanauskaite, Sophia Neisinger, Ellen Witte-Haendel, Ana M. Gimenez-Arnau, Carole Guillet, Claudio Alberto S. Parisi, Constance H. Katelaris, Daria Fomina, Desiree Larenas-Linnemann, Elizabeth Garcia, Emek Kocaturk, Frank Siebenhaar, Hermenio Lima, Igor Kaidashev, Iman Nasr, Isabel Ogueta Canales, Ivan Cherrez Ojeda, Jacques Hebert, Jean BousquetJonathan A. Bernstein, Jonny Peter, Jorge Sanchez, Jose Ignacio Larco Sousa, Kanokvalai Kulthanan, Karsten Weller, Kiran Godse, Krzysztof Rutkowski, Lasma Lapina, Laurence Bouillet, Leo Lianyi Han, Luis Felipe Ensina, Margarida Goncalo, Markus Magerl, Martijn van Doorn, Martin Metz, Maryam Khoshkhui, Michihiro Hide, Murat Turk, Niall Conlon, Pascale Salameh, Pavel Kolkhir, Riccardo Asero, Roman Stepanenko, Sabine Altrichter, Sara Gil-Mata, Simon Francis Thomsen, Torsten Zuberbier, Vladyslav Tsaryk, Young-Min Ye, Zenon Brzoza, Zuotao Zhao, Marcus Maurer

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: CRUSE® is an app that allows patients with chronic spontaneous urticaria (CSU) to monitor their daily disease activity through the use of visual analogue scales (VASs). We aimed to determine the concurrent validity, reliability, responsiveness and minimal important difference (MID) of CRUSE® VASs. Methods: We evaluated the properties of three daily VASs: VAS for how much patients were affected by their CSU (‘VAS urticaria’), VAS for the impact of urticaria on work/school productivity (‘VAS productivity’) and the VAS of EQ-5D. Concurrent validity was assessed by measuring the association between each VAS and the Urticaria Activity Score (UAS). Intra-rater reliability was determined based on the data of users providing multiple daily questionnaires within the same day. Test–retest reliability and responsiveness (ability to change), respectively, were tested in clinically stable and clinically unstable users. MIDs were determined using distribution-based methods. Results: We included 5938 patients (67,380 days). Concurrent validity was high, with VAS urticaria being more strongly associated with the UAS score than the remaining VASs. Intra-rater reliability was also high, with intraclass correlation coefficients (ICC) being above 0.950 for all VASs. Moderate-high test–retest reliability and responsiveness were observed, with reliability ICC being highest for VAS EQ-5D and responsiveness being highest for VAS urticaria. The MID for VAS urticaria was 17 (out of 100) units, compared to 15 units for VAS productivity and 11 units for VAS EQ-5D. Conclusion: Daily VASs for CSU available in the CRUSE® app display high concurrent validity and intra-rater reliability and moderate-high test–retest reliability and responsiveness.

Original language	English
Article number	all.16371
Number of pages	12
Journal	Allergy
Early online date	24 Oct 2024
DOIs	https://doi.org/10.1111/all.16371
Publication status	E-pub ahead of print - 24 Oct 2024

Bibliographical note

Publisher Copyright:
© 2024 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Access to Document

10.1111/all.16371

Cite this

Sousa-Pinto, B., Ramanauskaite, A., Neisinger, S., Witte-Haendel, E., Gimenez-Arnau, A. M., Guillet, C., Parisi, C. A. S., Katelaris, C. H., Fomina, D., Larenas-Linnemann, D., Garcia, E., Kocaturk, E., Siebenhaar, F., Lima, H., Kaidashev, I., Nasr, I., Canales, I. O., Ojeda, I. C., Hebert, J., ... Maurer, M. (2024). Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE® mobile health study. Allergy, Article all.16371. Advance online publication. https://doi.org/10.1111/all.16371

@article{0bf67f8190a04acf9b98ebb0fe0d4d3e,

title = "Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE{\textregistered} mobile health study",

abstract = "Background: CRUSE{\textregistered} is an app that allows patients with chronic spontaneous urticaria (CSU) to monitor their daily disease activity through the use of visual analogue scales (VASs). We aimed to determine the concurrent validity, reliability, responsiveness and minimal important difference (MID) of CRUSE{\textregistered} VASs. Methods: We evaluated the properties of three daily VASs: VAS for how much patients were affected by their CSU ({\textquoteleft}VAS urticaria{\textquoteright}), VAS for the impact of urticaria on work/school productivity ({\textquoteleft}VAS productivity{\textquoteright}) and the VAS of EQ-5D. Concurrent validity was assessed by measuring the association between each VAS and the Urticaria Activity Score (UAS). Intra-rater reliability was determined based on the data of users providing multiple daily questionnaires within the same day. Test–retest reliability and responsiveness (ability to change), respectively, were tested in clinically stable and clinically unstable users. MIDs were determined using distribution-based methods. Results: We included 5938 patients (67,380 days). Concurrent validity was high, with VAS urticaria being more strongly associated with the UAS score than the remaining VASs. Intra-rater reliability was also high, with intraclass correlation coefficients (ICC) being above 0.950 for all VASs. Moderate-high test–retest reliability and responsiveness were observed, with reliability ICC being highest for VAS EQ-5D and responsiveness being highest for VAS urticaria. The MID for VAS urticaria was 17 (out of 100) units, compared to 15 units for VAS productivity and 11 units for VAS EQ-5D. Conclusion: Daily VASs for CSU available in the CRUSE{\textregistered} app display high concurrent validity and intra-rater reliability and moderate-high test–retest reliability and responsiveness.",

author = "Bernardo Sousa-Pinto and Aiste Ramanauskaite and Sophia Neisinger and Ellen Witte-Haendel and Gimenez-Arnau, {Ana M.} and Carole Guillet and Parisi, {Claudio Alberto S.} and Katelaris, {Constance H.} and Daria Fomina and Desiree Larenas-Linnemann and Elizabeth Garcia and Emek Kocaturk and Frank Siebenhaar and Hermenio Lima and Igor Kaidashev and Iman Nasr and Canales, {Isabel Ogueta} and Ojeda, {Ivan Cherrez} and Jacques Hebert and Jean Bousquet and Bernstein, {Jonathan A.} and Jonny Peter and Jorge Sanchez and Sousa, {Jose Ignacio Larco} and Kanokvalai Kulthanan and Karsten Weller and Kiran Godse and Krzysztof Rutkowski and Lasma Lapina and Laurence Bouillet and Han, {Leo Lianyi} and Ensina, {Luis Felipe} and Margarida Goncalo and Markus Magerl and {van Doorn}, Martijn and Martin Metz and Maryam Khoshkhui and Michihiro Hide and Murat Turk and Niall Conlon and Pascale Salameh and Pavel Kolkhir and Riccardo Asero and Roman Stepanenko and Sabine Altrichter and Sara Gil-Mata and Thomsen, {Simon Francis} and Torsten Zuberbier and Vladyslav Tsaryk and Young-Min Ye and Zenon Brzoza and Zuotao Zhao and Marcus Maurer",

note = "Publisher Copyright: {\textcopyright} 2024 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.",

year = "2024",

month = oct,

day = "24",

doi = "10.1111/all.16371",

language = "English",

journal = "Allergy",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

}

Sousa-Pinto, B, Ramanauskaite, A, Neisinger, S, Witte-Haendel, E, Gimenez-Arnau, AM, Guillet, C, Parisi, CAS, Katelaris, CH, Fomina, D, Larenas-Linnemann, D, Garcia, E, Kocaturk, E, Siebenhaar, F, Lima, H, Kaidashev, I, Nasr, I, Canales, IO, Ojeda, IC, Hebert, J, Bousquet, J, Bernstein, JA, Peter, J, Sanchez, J, Sousa, JIL, Kulthanan, K, Weller, K, Godse, K, Rutkowski, K, Lapina, L, Bouillet, L, Han, LL, Ensina, LF, Goncalo, M, Magerl, M, van Doorn, M, Metz, M, Khoshkhui, M, Hide, M, Turk, M, Conlon, N, Salameh, P, Kolkhir, P, Asero, R, Stepanenko, R, Altrichter, S, Gil-Mata, S, Thomsen, SF, Zuberbier, T, Tsaryk, V, Ye, Y-M, Brzoza, Z, Zhao, Z & Maurer, M 2024, 'Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE® mobile health study', Allergy. https://doi.org/10.1111/all.16371

TY - JOUR

T1 - Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring

T2 - A CRUSE® mobile health study

AU - Sousa-Pinto, Bernardo

AU - Ramanauskaite, Aiste

AU - Neisinger, Sophia

AU - Witte-Haendel, Ellen

AU - Gimenez-Arnau, Ana M.

AU - Guillet, Carole

AU - Parisi, Claudio Alberto S.

AU - Katelaris, Constance H.

AU - Fomina, Daria

AU - Larenas-Linnemann, Desiree

AU - Garcia, Elizabeth

AU - Kocaturk, Emek

AU - Siebenhaar, Frank

AU - Lima, Hermenio

AU - Kaidashev, Igor

AU - Nasr, Iman

AU - Canales, Isabel Ogueta

AU - Ojeda, Ivan Cherrez

AU - Hebert, Jacques

AU - Bousquet, Jean

AU - Bernstein, Jonathan A.

AU - Peter, Jonny

AU - Sanchez, Jorge

AU - Sousa, Jose Ignacio Larco

AU - Kulthanan, Kanokvalai

AU - Weller, Karsten

AU - Godse, Kiran

AU - Rutkowski, Krzysztof

AU - Lapina, Lasma

AU - Bouillet, Laurence

AU - Han, Leo Lianyi

AU - Ensina, Luis Felipe

AU - Goncalo, Margarida

AU - Magerl, Markus

AU - van Doorn, Martijn

AU - Metz, Martin

AU - Khoshkhui, Maryam

AU - Hide, Michihiro

AU - Turk, Murat

AU - Conlon, Niall

AU - Salameh, Pascale

AU - Kolkhir, Pavel

AU - Asero, Riccardo

AU - Stepanenko, Roman

AU - Altrichter, Sabine

AU - Gil-Mata, Sara

AU - Thomsen, Simon Francis

AU - Zuberbier, Torsten

AU - Tsaryk, Vladyslav

AU - Ye, Young-Min

AU - Brzoza, Zenon

AU - Zhao, Zuotao

AU - Maurer, Marcus

PY - 2024/10/24

Y1 - 2024/10/24

N2 - Background: CRUSE® is an app that allows patients with chronic spontaneous urticaria (CSU) to monitor their daily disease activity through the use of visual analogue scales (VASs). We aimed to determine the concurrent validity, reliability, responsiveness and minimal important difference (MID) of CRUSE® VASs. Methods: We evaluated the properties of three daily VASs: VAS for how much patients were affected by their CSU (‘VAS urticaria’), VAS for the impact of urticaria on work/school productivity (‘VAS productivity’) and the VAS of EQ-5D. Concurrent validity was assessed by measuring the association between each VAS and the Urticaria Activity Score (UAS). Intra-rater reliability was determined based on the data of users providing multiple daily questionnaires within the same day. Test–retest reliability and responsiveness (ability to change), respectively, were tested in clinically stable and clinically unstable users. MIDs were determined using distribution-based methods. Results: We included 5938 patients (67,380 days). Concurrent validity was high, with VAS urticaria being more strongly associated with the UAS score than the remaining VASs. Intra-rater reliability was also high, with intraclass correlation coefficients (ICC) being above 0.950 for all VASs. Moderate-high test–retest reliability and responsiveness were observed, with reliability ICC being highest for VAS EQ-5D and responsiveness being highest for VAS urticaria. The MID for VAS urticaria was 17 (out of 100) units, compared to 15 units for VAS productivity and 11 units for VAS EQ-5D. Conclusion: Daily VASs for CSU available in the CRUSE® app display high concurrent validity and intra-rater reliability and moderate-high test–retest reliability and responsiveness.

AB - Background: CRUSE® is an app that allows patients with chronic spontaneous urticaria (CSU) to monitor their daily disease activity through the use of visual analogue scales (VASs). We aimed to determine the concurrent validity, reliability, responsiveness and minimal important difference (MID) of CRUSE® VASs. Methods: We evaluated the properties of three daily VASs: VAS for how much patients were affected by their CSU (‘VAS urticaria’), VAS for the impact of urticaria on work/school productivity (‘VAS productivity’) and the VAS of EQ-5D. Concurrent validity was assessed by measuring the association between each VAS and the Urticaria Activity Score (UAS). Intra-rater reliability was determined based on the data of users providing multiple daily questionnaires within the same day. Test–retest reliability and responsiveness (ability to change), respectively, were tested in clinically stable and clinically unstable users. MIDs were determined using distribution-based methods. Results: We included 5938 patients (67,380 days). Concurrent validity was high, with VAS urticaria being more strongly associated with the UAS score than the remaining VASs. Intra-rater reliability was also high, with intraclass correlation coefficients (ICC) being above 0.950 for all VASs. Moderate-high test–retest reliability and responsiveness were observed, with reliability ICC being highest for VAS EQ-5D and responsiveness being highest for VAS urticaria. The MID for VAS urticaria was 17 (out of 100) units, compared to 15 units for VAS productivity and 11 units for VAS EQ-5D. Conclusion: Daily VASs for CSU available in the CRUSE® app display high concurrent validity and intra-rater reliability and moderate-high test–retest reliability and responsiveness.

UR - http://www.scopus.com/inward/record.url?scp=85207494050&partnerID=8YFLogxK

U2 - 10.1111/all.16371

DO - 10.1111/all.16371

M3 - Article

C2 - 39445583

SN - 0105-4538

JO - Allergy

JF - Allergy

M1 - all.16371

ER -

Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE® mobile health study

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this